Frank Joseph Daugherty - 22 Jun 2022 Form 4 Insider Report for Greenwich LifeSciences, Inc. (GLSI)

Role: Chief Medical Officer, Director
Signature: /s/ Frank Daugherty
Issuer symbol: GLSI
Transactions as of: 22 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 24 Jun 2022, 08:18:47 UTC
Previous filing: 26 Apr 2022
Next filing: 27 Dec 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GLSI	Stock Options	Award	$0	+104,890		$0.000000	104,890	22 Jun 2022	Common Stock	104,890	$7.63	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options vest over time and pursuant to milestones. 2,185 of the options vest each month for 48 months contingent on the Company meeting certain performance milestones. The Reporting Person is eligible to exercise (i) 25% after the first site is activated for the Phase 3 clinical trial, (ii) 50% after completion of interim analysis of the Phase 3 clinical trial and (iii) 25% upon filing of Biologic License Application with the US Food and Drug Administration.

Content

The options vest over time and pursuant to milestones. 2,185 of the options vest each month for 48 months contingent on the Company meeting certain performance milestones. The Reporting Person is eligible to exercise (i) 25% after the first site is activated for the Phase 3 clinical trial, (ii) 50% after completion of interim analysis of the Phase 3 clinical trial and (iii) 25% upon filing of Biologic License Application with the US Food and Drug Administration.